======= WDR82 =======
== Gene Information ==
* **Official Symbol**: WDR82
* **Official Name**: WD repeat domain 82
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=80335|80335]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q6UXN9|Q6UXN9]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=WDR82&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20WDR82|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/611059|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Regulatory component of the SET1 complex implicated in the tethering of this complex to transcriptional start sites of active genes. Facilitates histone H3 'Lys-4' methylation via recruitment of the SETD1A or SETD1B to the 'Ser-5' phosphorylated C-terminal domain (CTD) of RNA polymerase II large subunit (POLR2A). Component of PTW/PP1 phosphatase complex, which plays a role in the control of chromatin structure and cell cycle progression during the transition from mitosis into interphase. {ECO:0000269|PubMed:17998332, ECO:0000269|PubMed:18838538, ECO:0000269|PubMed:20516061}.
|WD40|
|PTW/PP1 phosphatase complex|
|Set1C/COMPASS complex|
|histone H3-K4 trimethylation|
|histone methyltransferase activity (H3-K4 specific)|
|peptidyl-lysine trimethylation|
|histone H3-K4 methylation|
|histone methyltransferase complex|
|histone lysine methylation|
|peptidyl-lysine methylation|
|histone methylation|
|nuclear chromosome, telomeric region|
|chromatin|
|protein alkylation|
|protein methylation|
|macromolecule methylation|
|methylation|
|peptidyl-lysine modification|
|histone modification|
|covalent chromatin modification|
|chromatin binding|
|chromatin organization|
|nucleolus|
|peptidyl-amino acid modification|
|chromosome organization|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp417|Tubastatin-A 2.5μM R07 exp417]]|-2.43|
|[[:results:exp47|Lapatinib 5μM R01 exp47]]|-2.31|
|[[:results:exp42|BI-6727 0.001μM R01 exp42]]|-2.2|
|[[:results:exp307|Rapamycin 2μM plus Cyclosporin-A 3μM R07 exp307]]|-2.1|
|[[:results:exp474|CR131-b 0.005μM R08 exp474]]|-2.02|
|[[:results:exp317|Geldanamycin 0.015 to 0.05μM on day4 R07 exp317]]|-1.97|
|[[:results:exp405|Tenofovir 10μM R07 exp405]]|-1.88|
|[[:results:exp216|Erlotinib 10μM R05 exp216]]|-1.86|
|[[:results:exp243|S-trityl-L-cysteine 0.5μM R05 exp243]]|-1.72|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|-1.71|
|[[:results:exp399|Salubrinal 20μM R07 exp399]]|-1.7|
|[[:results:exp96|BI-2536 0.02μM R03 exp96]]|1.71|
|[[:results:exp108|Vinblastine 0.2μM R03 exp108]]|1.71|
|[[:results:exp350|Deferoxamine 11μM R07 exp350]]|1.79|
|[[:results:exp466|Cannabidiol 20μM R08 exp466]]|1.84|
|[[:results:exp443|SNS-032 15μM R08 exp443]]|1.87|
|[[:results:exp478|Doxorubicin 0.02μM R08 exp478]]|2.01|
|[[:results:exp502|Milciclib 2μM R08 exp502]]|2.08|
|[[:results:exp441|GSK-J4 1.5μM R08 exp441]]|2.26|
|[[:results:exp521|Salinomycin 3.5μM R08 exp521]]|2.28|
|[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|2.53|
|[[:results:exp98|BI-6727 0.04μM R03 exp98]]|2.61|
|[[:results:exp244|SB743921 0.001μM R05 exp244]]|2.74|
|[[:results:exp435|JQ1 0.8μM R08 exp435]]|2.8|
|[[:results:exp208|Vinblastine 0.015μM R05 exp208]]|3.02|
|[[:results:exp199|Etoposide 0.3μM R05 exp199]]|3.14|
^Gene^Correlation^
|[[:human genes:t:thg1l|THG1L]]|0.51|
|[[:human genes:p:pmm2|PMM2]]|0.477|
|[[:human genes:d:dpagt1|DPAGT1]]|0.475|
|[[:human genes:m:med16|MED16]]|0.45|
|[[:human genes:r:rnmt|RNMT]]|0.445|
|[[:human genes:k:kdm8|KDM8]]|0.444|
|[[:human genes:p:pelo|PELO]]|0.443|
|[[:human genes:r:rtcb|RTCB]]|0.434|
|[[:human genes:a:alg1|ALG1]]|0.432|
|[[:human genes:f:fnta|FNTA]]|0.431|
|[[:human genes:g:gnb1l|GNB1L]]|0.43|
|[[:human genes:p:ppcs|PPCS]]|0.429|
|[[:human genes:r:rpp21|RPP21]]|0.428|
|[[:human genes:m:mis18a|MIS18A]]|0.428|
|[[:human genes:d:dohh|DOHH]]|0.427|
|[[:human genes:a:atxn10|ATXN10]]|0.427|
|[[:human genes:o:oraov1|ORAOV1]]|0.421|
|[[:human genes:d:ddx20|DDX20]]|0.42|
|[[:human genes:a:adsl|ADSL]]|0.42|
|[[:human genes:t:tti1|TTI1]]|0.419|
|[[:human genes:u:utp23|UTP23]]|0.419|
|[[:human genes:u:uap1|UAP1]]|0.419|
|[[:human genes:g:gmppb|GMPPB]]|0.418|
|[[:human genes:r:rptor|RPTOR]]|0.416|
|[[:human genes:c:c21orf59|C21orf59]]|0.414|
|[[:human genes:u:uhrf1|UHRF1]]|0.412|
|[[:human genes:a:alg13|ALG13]]|0.41|
|[[:human genes:g:gfpt1|GFPT1]]|0.41|
|[[:human genes:t:trnt1|TRNT1]]|0.409|
|[[:human genes:m:maml1|MAML1]]|0.408|
|[[:human genes:e:exoc3|EXOC3]]|0.408|
|[[:human genes:c:cbfb|CBFB]]|0.408|
|[[:human genes:t:tti2|TTI2]]|0.407|
|[[:human genes:g:gemin5|GEMIN5]]|0.406|
|[[:human genes:p:pdpk1|PDPK1]]|0.406|
|[[:human genes:t:telo2|TELO2]]|0.405|
|[[:human genes:e:ercc2|ERCC2]]|0.402|
Global Fraction of Cell Lines Where Essential: 721/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|1/1|
|909776.0|1/1|
|bile duct|28/28|
|blood|28/28|
|bone|25/25|
|breast|32/33|
|central nervous system|56/56|
|cervix|4/4|
|colorectal|17/17|
|esophagus|13/13|
|fibroblast|1/1|
|gastric|14/15|
|kidney|21/21|
|liver|20/20|
|lung|75/75|
|lymphocyte|14/14|
|ovary|26/26|
|pancreas|24/24|
|peripheral nervous system|16/16|
|plasma cell|15/15|
|prostate|1/1|
|skin|24/24|
|soft tissue|7/7|
|thyroid|2/2|
|upper aerodigestive|22/22|
|urinary tract|29/29|
|uterus|5/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 2017
* **Expression level (log2 read counts)**: 7.83
{{:chemogenomics:nalm6 dist.png?nolink |}}